Dexcom (DXCM) Long-Term Debt Issuances (2017 - 2018)

Dexcom's (DXCM) quarterly Long-Term Debt Issuances came in at $836.6 million in Q4 2018, up 115.06% on a QoQ basis from $389.0 million in Q3 2017.

Dexcom (DXCM) Long-Term Debt Issuances (2017 - 2018) Analysis & Trends

Dexcom (DXCM) has 2 years of Long-Term Debt Issuances data on file, last reported at $836.6 million in Q4 2018.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $836.6 million in Q4 2018; TTM through Sep 2020 was $836.6 million, a 0.0% change from a year earlier, with the FY2023 full-year figure at $1.2 billion, changed N/A from the prior year.
Long-Term Debt Issuances for Q4 2018 stood at $836.6 million, up from $389.0 million in the prior quarter.
Over the last five years, Long-Term Debt Issuances for DXCM reached as high as $836.6 million in Q4 2018 and fell as low as $75.0 million in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	19.86 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	-
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	11.71 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	1.15 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Steris	20.59 Bn	20.16 Bn	697.10 Mn	-

Download Data